Prestige Consumer Healthcare (PBH) has moved to reshape its balance sheet and international footprint by closing the LaCorium Health acquisition and arranging new debt financing, including a planned senior notes offering and term loan amendment.

The LaCorium deal and new debt plans come at a time when Prestige Consumer Healthcare’s shares trade at US$49.92. The stock has posted a 6.28% 1 month share price return but a year to date share price decline of 18.46%, alongside a 1 year total shareholder return that is down 34.12%. This points to pressure on longer term holders even as shorter term momentum has picked up slightly.

If you want to broaden your watchlist beyond OTC healthcare, this may be a moment to scan for other opportunities in companies with strong balance sheets through the solid balance sheet and fundamentals stocks screener (47 results)

So are Prestige Consumer Healthcare’s latest moves a sign that the underlying OTC portfolio and cash generation can support more debt and acquisitions, or is the share price reacting more to changing sentiment around leverage and growth plans?

Most Popular Narrative: 25.3% Undervalued

Prestige Consumer Healthcare’s most followed narrative anchors on a fair value of $66.80, which sits well above the last close at $49.92 and frames the debate around how much future cash generation is already priced in.

Prestige's strong and consistent free cash flow generation (~$245 million projected for the year) provides financial flexibility for continued deleveraging and opportunistic share repurchases, supporting future earnings per share (EPS) growth and value for shareholders.

The core of this valuation story is straightforward yet rests on several assumptions. Steady revenue expansion, higher margins, and fewer shares all feed into a richer earnings base. Readers may be interested in how those moving parts combine into that fair value and what kind of profit multiple underpins it.

Result: Fair Value of $66.80 (UNDERVALUED)

However, there are still clear pressure points for Prestige Consumer Healthcare, including ongoing supply chain issues around key brands and heavier competition in e commerce channels that could challenge this upside story.

Next Steps

With both risks and rewards on the table for Prestige Consumer Healthcare, do you want to move quickly and test the narrative against the numbers yourself? Start by weighing the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Prestige Consumer Healthcare?

If Prestige Consumer Healthcare has sharpened your focus, do not stop here. Broaden your search with other focused stock ideas that fit your style and risk comfort.

• Target potential mispricings by reviewing companies highlighted in the 48 high quality undervalued stocks that some investors might be overlooking.
• Secure income focused opportunities by checking out the 8 dividend fortresses built around companies with higher yielding payouts.
• Dial down portfolio risk by scanning the 81 resilient stocks with low risk scores for businesses screened on more resilient characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.